Shanghai Institute of Organic Chemistry has prepared and tested microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer, traumatic brain injury, multiple sclerosis, and Alzheimer’s, Huntington's and Parkinson's disease.
Scientists from Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising antibodies targeting HER2 bound to an eribulin derivative through a linker reported to be useful for the treatment of cancer.
Baylor College of Medicine has synthesized activin receptor type-1 (ACVR1; ALK2; ACTR-I) and/or serine/threonine-protein kinase receptor R3 (ACVRL1; ALK1) inhibitors reported to be useful for the treatment of cancer, fibrodysplasia ossificans progressiva (FOP), atherosclerosis and iron deficiency anemia.
Kytopen Corp. has received a phase II Small Business Innovation Research (SBIR) grant of $1.6 million from the NIAID/NIH to support preclinical studies of its engineered natural killer (NK) cells. The funding will be used to conduct in vivo preclinical studies, which will be conducted by Charles River Laboratories
Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis (MS). Abata obtained FDA clearance for a first-in-human study of ABA-101 in patients with MS in July.
Spinal cord injury (SCI) is characterized by extensive demyelination and inflammatory responses. The clearance of microglial lipid droplets contributes to neural recovery and remyelination. Putting the focus on investigating microRNAs that regulate lipid homeostasis after SCI was the objective of a recently published study.
Kalm Therapeutics Inc. disclosed a $700,000 oversubscribed closing of its seed round, which will be used to complete regulatory activities outlined in Kalm’s pre-IND meeting with the U.S. FDA, fund personnel and transfer the company’s patch production to a manufacturer.
Arrowhead Pharmaceuticals Inc. announced its plans to advance its RNAi drug candidates ARO-INHBE and ARO-ALK7 into clinical trials for the treatment of obesity and metabolic diseases.
Researchers have developed and tested a taurultam-derived oxathiazine compound, GP-2250, for the potential treatment of ovarian cancer. Taurolidine, a substance derived from the amino acid taurine, has been shown to have antiproliferative and antineoplastic activity in vitro and in vivo against various cancer types. GP-2250 was tested in vitro in several ovarian cancer cell lines, as well as in vivo as a monotherapy and in combination with standard-of-care drugs and PARP inhibitors.
With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from Dravet syndrome and other neurological conditions to cardiology indications and muscular dystrophies.
RSS
